• Accelero_Spring_2017_1.jpg
  • Accelero_Spring_2017_2.jpg
  • Accelero_Spring_2017_3.jpg
  • Accelero_Spring_2017_4.jpg
  • Accelero_Spring_2017_5.jpg
  • Accelero_Spring_2017_6.jpg
  • Accelero_Spring_2017_7.jpg
  • Accelero_Spring_2017_8.jpg
  • Accelero_Spring_2017_9.jpg

Accelero Bioanalytics GmbH is a small biotech startup located in Berlin on its best way to become a GLP certified test facility. Today Accelero´s team is pround to enter into a cooperation with Dr Knoell Consult GmbH, one of Europe´s leading service providers in the field of global pharmaceutical registration and marketing. For more information on Knoell Consult´s active drug compound advisory and registration opportunities, please visit the Knoell Consult Website).

Accelero Bioanalytics´ founder is pleased to be selected as a co-author for a first-in-human phase I clinical trial investigating a siRNA drug product formulation: Schultheis B et al, J Clin Oncol 2014 Nov 17 (Pubmed, J Clin Oncol).

Accelero Bioanalytics GmbH, an innovative bioanalytical contract research service provider, is proud to cooperate with Rhenus Office Systems´ GLP certified test site in Großbeeren near Berlin. Rhenus will be providing long-term archiving services for Accelero´s increasing GxP service pipeline.

In 2014 Accelero Bioanalytics team members will attend to events which will complete our expert knowledge. Get in touch with us to arrange an handshake appointment.

Accelero Bioanalytics GmbH, a small biotechnology platform focussing on custom-made ligand binding assay development and validation, is now proud to initiate the certification process according to the German Chemikaliengesetz (ChemG). Main topic is to receive an official GLP certificate granted by the German authority.

Accelero Bioanalytics GmbH, a highly innovative bioanalytical service provider for the Biotech industry located in the heart of Europe, reports today that the second time in a row the company can illustrate a positive net cash flow.

Welcome to our new design! We have been refreshing our website to enable a responsive interactive access with your mobile device. Please accept our apologies that the content has not been updated here and there. But we are permanently working on the updates ...

Accelero Bioanalytics GmbH, a young Biotech business focussing on innovative custom-made bioanalytical services, reported today that the company´s first financial year ended on 31 December 2012 was successfully closed with profit.

Earning before tax and provisions was 5 percent of business sales in 2012.

The Competence Center for Advanced Therapy Medicinal Product (ATMP) Development at the Berlin Center for Regenerative Therapies will host a symposium on "Trends and perspectives in the development, approval and reimbursement of ATMPs and combined medical devices".

Accelero Bioanalytics GmbH proudly announced today that the company has received full authorization from Berlin´s local LAGeSo authority for the bioanalytical processing of genetically modified organisms (GMO). The notification allows for the operation of safety level S2 laboratories (registration No. 661/12) according to the German genetic engineering safety regulations (Gentechniksicherheitsverordnung, GenTSV).